Developer docs
API playgroundTry for free, no card

Search company profiles

Abalos Therapeutics

Full company profile

uuid00024xa

Namestring
Abalos Therapeutics
Legal namestring
Abalos Therapeutics GmbH
Websiteurl
abalos-tx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Abalos Therapeutics GmbH is a privately held, clinical-stage biotechnology company headquartered in Düsseldorf, Germany, that is developing arenavirus-based immuno-oncology therapies for the treatment of solid tumors and metastases. Founded in 2019 by Professors Karl Lang (Chair of Immunology at University Duisburg-Essen) and Philipp Lang (Director of Molecular Medicine II at Heinrich Heine University Düsseldorf), the company translates academic research on antiviral immune responses into a novel class of systemically administered cancer immunotherapies designed to overcome the central limitations of current immuno-oncology approaches, namely immune evasion, suppressive tumor microenvironments, inadequate T-cell activation, and tumor heterogeneity.

The company's core technology is its proprietary AdaptInnate platform, which harnesses the unique properties of mammarenaviruses that preferentially infect and persist in cancer cells and antigen-presenting cells without lysing them, thereby triggering a concerted innate and adaptive immune response against primary tumors and distant metastases. The lead clinical candidate, ABX-001, is a systemically administrable, non-oncolytic immunotherapy that is differentiated from traditional oncolytic virotherapy by its non-lytic mechanism; ABX-001 entered Phase 1 clinical evaluation in October 2025 in patients with advanced solid tumors at a single site in Düsseldorf. The platform is intended to support a broader pipeline of both naturally optimized and payload-carrying therapeutics designed for specific cancer indications, including potential combinations with bispecific T-cell engagers as indicated by the company's preclinical data presentation at SITC 2025.

Abalos operates a pre-commercial business model with no product revenue; future revenue is anticipated through traditional pharmaceutical drug sales or licensing transactions following regulatory approval. The company is funded by a syndicate of European life science investors that led EUR 43 million in cumulative Series A financing between 2019 and 2021, supplemented by a EUR 1.2 million BMBF grant in 2024. Its primary stakeholders today are its venture investors (Boehringer Ingelheim Venture Fund, COPARION, Hx Bio Ventures, Seventure Partners, NRW.BANK, High-Tech Gründerfonds, Gründerfonds Ruhr, and Ventura), academic collaborators (the Universities of Duisburg-Essen and Düsseldorf), and clinical investigators; end customers will be oncology patients reached through standard pharmaceutical distribution channels post-approval.

Short descriptiontext

Abalos Therapeutics is a Düsseldorf-based clinical-stage biotechnology company developing arenavirus-based immuno-oncology therapies via its proprietary AdaptInnate platform, with lead candidate ABX-001 currently in Phase 1 clinical trials for patients with advanced solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDüsseldorf, Germany
HQ citystring
Düsseldorf
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology therapeutics, arenavirus cancer immunotherapy, viral immuno-oncology platform, solid tumor treatment, clinical stage biotechnology
Industry3 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Computer Systems Design Services541512
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development
TypeOne Time License
Description

Pre-revenue biotech company developing novel immunotherapies for cancer treatment. The company is in early clinical stages with lead candidate ABX-001 in Phase 1 trials for solid tumors. Revenue generation is anticipated through future drug sales upon regulatory approval.

abalos-tx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Abalos Therapeutics develops systemically administrable immuno-virotherapies that use proprietary arenavirus vectors to trigger precise innate and adaptive immune responses against solid tumors. Its lead candidate, ABX-001, is a non-oncolytic arenavirus-based therapy in Phase 1 clinical trials for patients with advanced solid tumors. The proprietary AdaptInnate platform underpins a pipeline of naturally optimized and payload-carrying therapeutics for specific cancer indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Marked tumor regression in multiple preclinical tumor models
+2 more records
Product overview1 text field

Abalos Therapeutics is developing a novel class of systemically administrable immuno-oncology candidates that trigger precise innate and adaptive immune responses from within a patient's tumor. The company's lead product is ABX-001, the first candidate from its proprietary AdaptInnate platform, currently in Phase 1 clinical trials for advanced solid tumors. The pipeline includes both naturally optimized as well as payload-carrying therapeutics designed for specific cancer indications. The AdaptInnate platform leverages arenavirus technology to stimulate comprehensive immune responses against primary tumors and distant metastases.

Product and service2 records
1ABX-001
CategoryImmuno-oncology drug candidate
Description

Lead product candidate based on the AdaptInnate approach. A systemically administrable, non-oncolytic arenavirus-based immunotherapy designed to persist and replicate in cancerous and antigen-presenting cells without destroying them, triggering targeted, effective, and durable anti-tumor activity involving both innate and adaptive immune systems. Currently in Phase 1 clinical trials for advanced solid tumors.

2AdaptInnate Platform
CategoryProprietary drug discovery platform
Description

Proprietary technology platform harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to trigger precise and directed immune responses against primary tumors and their metastases. Generates drug candidates that achieve persistent and far-reaching inflammation within the tumor, engaging all key immune organs in a concerted attack.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key academic partner where company co-founder Prof. Dr. Karl Lang serves as Chair of Immunology. One of the largest and youngest universities in Germany with top research rankings.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner where company co-founder Prof. Dr. Philipp Lang serves as Director of Department of Molecular Medicine II. Founded in 1965 with approximately 35,000 students.

3High-Tech Corporate Services
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Operative services company specializing in establishment, structuring and management of administrative and financial divisions for startups, having supported over 100 startups.

abalos-tx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Rigontec (acquired by MSD/Merck)
TypeEmerging player
Description

Developed RIG-I RNA agonist immunotherapies for cancer; acquired by MSD in 2017. Abalos's CSO Jörg Vollmer was previously CSO at Rigontec, making it a directly comparable prior-stage precedent for Abalos's viral-immunotherapy approach and exit pathway.

TypeEmerging player
Description

Developed the oncolytic VSV-GP virus platform; acquired by Boehringer Ingelheim. Abalos's CTO Dethardt Müller previously led CMC at ViraTherapeutics, making it the most direct operational precedent for Abalos's virus-based immuno-oncology strategy.

3Targovax
TypeDirect peer
Description

Clinical-stage biotech developing oncolytic viruses and immune activators for solid tumors. Directly comparable in modality (virus-based cancer immunotherapy) and stage, though Targovax focuses on oncolytic rather than non-oncolytic mechanisms.

TypeDirect peer
Description

Clinical-stage company developing oncolytic immunotherapies for solid tumors. Comparable in virus-based cancer immunotherapy modality and in targeting of solid tumor indications, though using oncolytic rather than non-oncolytic mechanisms.

5PsiOxus Therapeutics
TypeDirect peer
Description

Develops enadenotucirev and other oncolytic virus immunotherapies for solid tumors. Directly comparable in virus-based cancer immunotherapy modality and in targeting of solid tumor indications.

TypeDirect peer
Description

Clinical-stage developer of oncolytic virus therapies including measles and vesicular stomatitis virus constructs. Comparable in virus-based cancer immunotherapy modality and oncology focus.

7Cold Genesys
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing oncolytic virus therapies (CG0070) for solid tumors including bladder cancer. Comparable in virus-based cancer immunotherapy modality.

TypeDirect peer
Description

Developed Pexa-Vec, a GM-CSF-expressing oncolytic vaccinia virus for solid tumors. Comparable in virus-based cancer immunotherapy modality and oncology indication focus.

9Istari Oncology
TypeDirect peer
Description

Clinical-stage company developing PVSRIPO, a poliovirus-based immunotherapy for solid tumors. Comparable in virus-based cancer immunotherapy modality targeting solid tumors.

10Turnstone Biologics
TypeEmerging player
Description

Clinical-stage biotech developing viral immunotherapies and tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable in viral immunotherapy modality and solid tumor focus, with overlapping investor profiles.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abalos Therapeutics

Immuno-oncology Therapeuticsabalos-tx.com

Abalos Therapeutics is a Düsseldorf-based clinical-stage biotechnology company developing arenavirus-based immuno-oncology therapies via its proprietary AdaptInnate platform, with lead candidate ABX-001 currently in Phase 1 clinical trials for patients with advanced solid tumors.

What Abalos Therapeutics does

Abalos Therapeutics GmbH is a privately held, clinical-stage biotechnology company headquartered in Düsseldorf, Germany, that is developing arenavirus-based immuno-oncology therapies for the treatment of solid tumors and metastases. Founded in 2019 by Professors Karl Lang (Chair of Immunology at University Duisburg-Essen) and Philipp Lang (Director of Molecular Medicine II at Heinrich Heine University Düsseldorf), the company translates academic research on antiviral immune responses into a novel class of systemically administered cancer immunotherapies designed to overcome the central limitations of current immuno-oncology approaches, namely immune evasion, suppressive tumor microenvironments, inadequate T-cell activation, and tumor heterogeneity.

The company's core technology is its proprietary AdaptInnate platform, which harnesses the unique properties of mammarenaviruses that preferentially infect and persist in cancer cells and antigen-presenting cells without lysing them, thereby triggering a concerted innate and adaptive immune response against primary tumors and distant metastases. The lead clinical candidate, ABX-001, is a systemically administrable, non-oncolytic immunotherapy that is differentiated from traditional oncolytic virotherapy by its non-lytic mechanism; ABX-001 entered Phase 1 clinical evaluation in October 2025 in patients with advanced solid tumors at a single site in Düsseldorf. The platform is intended to support a broader pipeline of both naturally optimized and payload-carrying therapeutics designed for specific cancer indications, including potential combinations with bispecific T-cell engagers as indicated by the company's preclinical data presentation at SITC 2025.

Abalos operates a pre-commercial business model with no product revenue; future revenue is anticipated through traditional pharmaceutical drug sales or licensing transactions following regulatory approval. The company is funded by a syndicate of European life science investors that led EUR 43 million in cumulative Series A financing between 2019 and 2021, supplemented by a EUR 1.2 million BMBF grant in 2024. Its primary stakeholders today are its venture investors (Boehringer Ingelheim Venture Fund, COPARION, Hx Bio Ventures, Seventure Partners, NRW.BANK, High-Tech Gründerfonds, Gründerfonds Ruhr, and Ventura), academic collaborators (the Universities of Duisburg-Essen and Düsseldorf), and clinical investigators; end customers will be oncology patients reached through standard pharmaceutical distribution channels post-approval.

Abalos Therapeutics firmographics

Firmographics
Name
Abalos Therapeutics
Legal name
Abalos Therapeutics GmbH
Website
https://abalos-tx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Abalos Therapeutics is a Düsseldorf-based clinical-stage biotechnology company developing arenavirus-based immuno-oncology therapies via its proprietary AdaptInnate platform, with lead candidate ABX-001 currently in Phase 1 clinical trials for patients with advanced solid tumors.
Ownership category
akta.pro rank

Abalos Therapeutics industry classification

Industry
Product category
Immuno-oncology Therapeutics
NAICS
Computer Systems Design and Related Services (54151), Computer Systems Design Services (541512)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Immuno-oncology therapeutics
  • Arenavirus cancer immunotherapy
  • Viral immuno-oncology platform
  • Solid tumor treatment
  • Clinical stage biotechnology

Where Abalos Therapeutics is headquartered

Location

Headquarters

HQ city
Düsseldorf
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Abalos Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Drug Development: Pre-revenue biotech company developing novel immunotherapies for cancer treatment. The company is in early clinical stages with lead candidate ABX-001 in Phase 1 trials for solid tumors. Revenue generation is anticipated through future drug sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Abalos Therapeutics product offering

Product offering

Core offering

Abalos Therapeutics develops systemically administrable immuno-virotherapies that use proprietary arenavirus vectors to trigger precise innate and adaptive immune responses against solid tumors. Its lead candidate, ABX-001, is a non-oncolytic arenavirus-based therapy in Phase 1 clinical trials for patients with advanced solid tumors. The proprietary AdaptInnate platform underpins a pipeline of naturally optimized and payload-carrying therapeutics for specific cancer indications.

Product overview

Abalos Therapeutics is developing a novel class of systemically administrable immuno-oncology candidates that trigger precise innate and adaptive immune responses from within a patient's tumor. The company's lead product is ABX-001, the first candidate from its proprietary AdaptInnate platform, currently in Phase 1 clinical trials for advanced solid tumors. The pipeline includes both naturally optimized as well as payload-carrying therapeutics designed for specific cancer indications. The AdaptInnate platform leverages arenavirus technology to stimulate comprehensive immune responses against primary tumors and distant metastases.

Differentiator

Problem solved

Functional benefit

Products and services

  • ABX-001 Lead product candidate based on the AdaptInnate approach. A systemically administrable, non-oncolytic arenavirus-based immunotherapy designed to persist and replicate in cancerous and antigen-presenting cells without destroying them, triggering targeted, effective, and durable anti-tumor activity involving both innate and adaptive immune systems. Currently in Phase 1 clinical trials for advanced solid tumors.
  • AdaptInnate Platform Proprietary technology platform harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to trigger precise and directed immune responses against primary tumors and their metastases. Generates drug candidates that achieve persistent and far-reaching inflammation within the tumor, engaging all key immune organs in a concerted attack.

Quantifiable outcome

  • Marked tumor regression in multiple preclinical tumor models
  • +2 more outcomes

Companies that use Abalos Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Abalos Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Abalos Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • University of Duisburg-EssencoreStrategic or Co-development PartnerKey academic partner where company co-founder Prof. Dr. Karl Lang serves as Chair of Immunology. One of the largest and youngest universities in Germany with top research rankings.
  • University of Düsseldorf (Heinrich Heine University)coreStrategic or Co-development PartnerAcademic partner where company co-founder Prof. Dr. Philipp Lang serves as Director of Department of Molecular Medicine II. Founded in 1965 with approximately 35,000 students.
  • High-Tech Corporate ServicessupportingImplementation/ SI/ Consulting PartnerOperative services company specializing in establishment, structuring and management of administrative and financial divisions for startups, having supported over 100 startups.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Abalos Therapeutics competitors and assessment

Company assessment

Emerging players

  • Rigontec (acquired by MSD/Merck): Developed RIG-I RNA agonist immunotherapies for cancer; acquired by MSD in 2017. Abalos's CSO Jörg Vollmer was previously CSO at Rigontec, making it a directly comparable prior-stage precedent for Abalos's viral-immunotherapy approach and exit pathway.
  • ViraTherapeutics (acquired by Boehringer Ingelheim): Developed the oncolytic VSV-GP virus platform; acquired by Boehringer Ingelheim. Abalos's CTO Dethardt Müller previously led CMC at ViraTherapeutics, making it the most direct operational precedent for Abalos's virus-based immuno-oncology strategy.
  • Turnstone Biologics: Clinical-stage biotech developing viral immunotherapies and tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable in viral immunotherapy modality and solid tumor focus, with overlapping investor profiles.

Direct peers

  • Targovax: Clinical-stage biotech developing oncolytic viruses and immune activators for solid tumors. Directly comparable in modality (virus-based cancer immunotherapy) and stage, though Targovax focuses on oncolytic rather than non-oncolytic mechanisms.
  • Replimune: Clinical-stage company developing oncolytic immunotherapies for solid tumors. Comparable in virus-based cancer immunotherapy modality and in targeting of solid tumor indications, though using oncolytic rather than non-oncolytic mechanisms.
  • PsiOxus Therapeutics: Develops enadenotucirev and other oncolytic virus immunotherapies for solid tumors. Directly comparable in virus-based cancer immunotherapy modality and in targeting of solid tumor indications.
  • Vyriad: Clinical-stage developer of oncolytic virus therapies including measles and vesicular stomatitis virus constructs. Comparable in virus-based cancer immunotherapy modality and oncology focus.
  • Cold Genesys: Clinical-stage immuno-oncology company developing oncolytic virus therapies (CG0070) for solid tumors including bladder cancer. Comparable in virus-based cancer immunotherapy modality.
  • SillaJen: Developed Pexa-Vec, a GM-CSF-expressing oncolytic vaccinia virus for solid tumors. Comparable in virus-based cancer immunotherapy modality and oncology indication focus.
  • Istari Oncology: Clinical-stage company developing PVSRIPO, a poliovirus-based immunotherapy for solid tumors. Comparable in virus-based cancer immunotherapy modality targeting solid tumors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

Abalos Therapeutics social profiles

Digital presence

Abalos Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abalos Therapeutics leadership team

Management profile

Number of profiles

Profiles15 records

Abalos Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abalos Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abalos Therapeutics

What does Abalos Therapeutics do?

Abalos Therapeutics develops systemically administrable immuno-virotherapies that use proprietary arenavirus vectors to trigger precise innate and adaptive immune responses against solid tumors. Its lead candidate, ABX-001, is a non-oncolytic arenavirus-based therapy in Phase 1 clinical trials for patients with advanced solid tumors. The proprietary AdaptInnate platform underpins a pipeline of naturally optimized and payload-carrying therapeutics for specific cancer indications.

Is Abalos Therapeutics a public or private company?

Abalos Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Abalos Therapeutics founded?

Abalos Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Abalos Therapeutics based?

Abalos Therapeutics is headquartered in Düsseldorf, Germany, in the Europe region.

How does Abalos Therapeutics make money?

One revenue line is on record: pharmaceutical Drug Development.

Who are Abalos Therapeutics's main competitors?

Emerging players on record are Rigontec (acquired by MSD/Merck), ViraTherapeutics (acquired by Boehringer Ingelheim) and Turnstone Biologics. Direct peers are Targovax, Replimune, PsiOxus Therapeutics, Vyriad, Cold Genesys, SillaJen and Istari Oncology.

Does Abalos Therapeutics have an API?

No public API is recorded for Abalos Therapeutics.

What industry is Abalos Therapeutics in?

Abalos Therapeutics's product category is Immuno-oncology Therapeutics. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins. Its NAICS code is 54151 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAbalos Therapeutics to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025Abalos Therapeutics will present preclinical data on ABX-001 combined with bispecific T-cell engagers at SITC 2025, showing synergistic anti-tumor effects. The combination enhances T-cell recruitment and cytotoxicity, with ABX-001 alone recruiting CD8+ T-cells and showing safety in mice and non-human primates.GlobeNewswireAbalos Therapeutics to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025Abalos Therapeutics announced it will present preclinical data on its lead candidate ABX-001 combined with bispecific T-cell engagers at the SITC 2025 Annual Meeting, demonstrating synergistic anti-tumor effects with enhanced T-cell recruitment and cytotoxic activity. The company recently initiated a Phase 1 first-in-human study evaluating ABX-001 as monotherapy in patients with refractory/relapsed advanced solid tumors. ABX-001 showed preferential replication in tumor cells with minimal effects in healthy tissues and demonstrated an acceptable safety profile in preclinical studies.GlobeNewswireAbalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid TumorsAbalos Therapeutics announced that the first patient has been dosed in a first-in-human Phase 1 study evaluating ABX-001, the company's lead non-lytic viroimmunotherapy candidate, in patients with advanced solid tumors who have exhausted standard of care. The trial is an open-label, multicenter study designed to evaluate safety and tolerability and determine the recommended Phase 2 dose, enrolling approximately 18 patients who will receive a single intravenous administration in a dose-escalation approach. Early signs of efficacy will also be assessed based on overall response criteria and changes in target lesion size over 12 weeks.GlobeNewswireAbalos Therapeutics Publishes in Cell Reports MedicineAbalos Therapeutics published preclinical proof-of-concept data for its arenavirus-based drug candidate ABX-001 in Cell Reports Medicine, demonstrating strong anti-tumoral efficacy and a favorable safety profile across murine tumor models and non-human primates. The drug candidate showed induction of tumor-specific T cells and immune-activating cytokines without severe adverse effects. The company is advancing ABX-001 into a Phase 1 first-in-human basket-style trial across European sites.BioSpaceAbalos Therapeutics Appoints Thomas Bogenrieder as Chief Medical OfficerAbalos Therapeutics appointed Thomas Bogenrieder, MD, PhD, as Chief Medical Officer. He brings over 17 years of clinical development experience in cancer immunotherapies and will guide clinical and regulatory strategies for the company's arenavirus-based product candidates. The appointment aims to strengthen leadership as the company ramps up medical and clinical operations.FinSMEsAbalos Therapeutics Raises €32.5M in Series A ExtensionAbalos Therapeutics raised €32.5M in a Series A extension, led by Seventure Partners, bringing total funding to €43M. The company will use the funds to advance its first product candidate into a Phase 1/2 trial in multiple solid tumors and expand its pipeline.Business Wire BlogAbalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 MillionAbalos Therapeutics has completed an extension to its Series A funding round, raising an additional EUR 32.5 million led by Seventure Partners. This brings the total capital raised in this round to EUR 43 million (USD 50 million), supported by investors including Coparion, Ventura BioMed Investors, and Boehringer Ingelheim Venture Fund. The proceeds will fund the advancement of its lead immuno-virotherapy candidate into Phase 1/2 trials for solid tumors and support further pipeline expansion.FierceBiotechBoehringer's VC wing backs anti-cancer virus startupAbalos Therapeutics raised €12 million in a Series A round led by Boehringer Ingelheim Venture Fund and Gruenderfonds Ruhr to develop anti-cancer viruses. The company's approach uses viruses that trigger immune responses rather than directly killing cancer cells. The funding will support clinical testing of its virus strains.